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Abstract
Background: Centratherum anthelminticum (L.) Kuntze (scientific synonyms: Vernonia anthelmintica; black cumin) is
one of the ingredients of an Ayurvedic preparation, called “Kayakalp”, commonly applied to treat skin disorders in
India and Southeast Asia. Despite its well known anti-inflammatory property on skin diseases, the anti-cancer effect
of C. anthelminticum seeds on skin cancer is less documented. The present study aims to investigate the anti-cancer
effect of Centratherum anthelminticum (L.) seeds chloroform fraction (CACF) on human melanoma cells and to
elucidate the molecular mechanism involved.
Methods: A chloroform fraction was extracted from C. anthelminticum (CACF). Bioactive compounds of the CACF
were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Human melanoma cell line A375
was treated with CACF in vitro. Effects of CACF on growth inhibition, morphology, stress and survival of the cell
were examined with MTT, high content screening (HSC) array scan and flow cytometry analyses. Involvement of
intrinsic or extrinsic pathways in the CACF-induced A375 cell death mechanism was examined using a caspase
luminescence assay. The results were further verified with different caspase inhibitors. In addition, Western blot
analysis was performed to elucidate the changes in apoptosis-associated molecules. Finally, the effect of CACF on
the NF-κB nuclear translocation ability was assayed.
Results: The MTT assay showed that CACF dose-dependently inhibited cell growth of A375, while exerted less
cytotoxic effect on normal primary epithelial melanocytes. We demonstrated that CACF induced cell growth
inhibition through apoptosis, as evidenced by cell shrinkage, increased annexin V staining and formation of
membrane blebs. CACF treatment also resulted in higher reactive oxygen species (ROS) production and lower Bcl-2
expression, leading to decrease mitochondrial membrane potential (MMP). Disruption of the MMP facilitated the
release of mitochondrial cytochrome c, which activates caspase-9 and downstream caspase-3/7, resulting in DNA
fragmentation and up-regulation of p53 in melanoma cells. Moreover, CACF prevented TNF-α-induced NF-κB
nuclear translocation, which further committed A375 cells toward apoptosis.
Conclusions: Together, our findings suggest CACF as a potential therapeutic agent against human
melanoma malignancy.
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Background
Melanoma is a skin cancer that arises from the malig-
nant transformation of melanocytes. Epidemiological
studies showed that the incidence of melanoma is in-
creasing at a rate faster than that of any other cancers
worldwide [1-3]. Moreover, although early stage melan-
oma is confined to epidermis and is curable, metasta-
sized melanoma has an unfavourable prognosis, where
the overall survival for patients with metastatic melan-
oma ranges from 4.7 to 11 months, with a median sur-
vival of 8.5 months [4]. This poor prognosis is due to
the lack of effective treatment options [5].
Melanoma is often characterized by resistance to cytoxic
agents which contributes to the high morbidity and mor-
tality rates in patients. Therefore it is important to look for
new sources of anti-cancer agents that exert cytotoxicity
activity against melanoma cells. Plant extracts have been
used as complementary medicine for many years. Various
phytoconstituents that possess multiple biological and
synergistical effects in the plant extracts can function to
treat different ailments or enhance the effect of drugs
[6-9]. Certain natural products have been applied for can-
cer chemoprevention to inhibit or revert carcinogenesis
and to suppress the malignancy of cancer [10].
Centratherum anthelminticum (L.) Kuntze seeds (sci-
entific synonyms: Vernonia anthelmintica) is commonly
known as black cumin and widely used as curry spice
mixtures. Studies have shown various pharmacological
properties exhibited in the seeds of C. anthelminticum,
such as anti-viral, anti-filarial, anti-microbial, anti-fungal
and anti-diabetic activities [11-15]. The black cumin
seed is famous for its anti-inflammatory effect. It is used
as an ingredient of an Ayurvedic preparation called
“Kayakalp” to treat skin disorders and for body rejuven-
ation in India and Southeast Asia. Recently, a report
showed that methanol extracts from C. anthelminticum
promoted melanogenesis mainly by p38 MAPK activa-
tion, providing scientific explanation for its traditional
use in skin disorders, such as leucoderma [16].
In comparison with other biological activities, the anti-
cancer effect of CACF is relatively less documented. We
recently reported that CACF inhibited the growth of
breast cancer cell lines [17]; however, its effect and de-
tailed mechanism on skin cancer is yet to be investigated.
Hence, the aim of this study is to evaluate the therapeutic
effect of CACF and the cellular mechanism underlying the
anti-cancer effect on melanoma malignancy.
Methods
Plant materials
The seeds of C. anthelminticum plant were procured
from the medicinal plant cultivation zone of Amritum
Bio-Botanica Herbs Research Laboratory Pvt. Ltd, Betul
Madhya Pradesh India. Voucher specimen (CA-9) was
deposited in the Department of Pharmacology, Univer-
sity Malaya.
Sample extraction
The seeds of C. anthelminticum (100 g) were pounded
using grinder and extracted with hexane (3 × 250 ml)
(Merck, Darmstadt, Germany) using soxhlet extractor.
Thereafter, the residue obtained was further fractionated
with chloroform (CHCl3) (3 × 250 ml) (Merck, Darmstadt,
Germany) and finally with methanol (MeOH) (3 × 250 ml)
(Merck, Darmstadt, Germany). The extract and crude frac-
tions were collected, filtered and concentrated to dryness
under reduced pressure in a rotary evaporator (<40°C).
The hexane extract (CAHE) yielded 20.1 g, whereas, the
defatted crude chloroform fraction (CACF) and the metha-
nol fraction (CAMF) yielded 7.7 g and 11.6 g, respectively.
Subsequent screening of the extract and fractions for their
cytotoxicity, using the MTT assay, showed that the chloro-
form fraction (CACF) possesses a maximum of inhibitory
effects against cancer cells. Therefore, CACF was chosen
for further analysis.
LC-MS/MS analysis
Liquid chromatography (LC) analysis was carried out
using UFLC prominence series (Shimadzu Corp., Kyoto,
Japan), equipped with a quaternary pump, a vacuum
degasser, an autosampler, a column heater-cooler and
PDA detector (diode array detector, DAD). Separation was
accomplished using an XBridge C18 column (Waters,
Ireland) (2.5 μm, 2.1 × 50 mm). About 1 mg of CACF was
dissolved in 1 ml MeOH filtered through a 0.45 mm filter
and subjected to high performance liquid chromatography
(HPLC). Gradient elution was performed using a linear
gradient solvent system consisting of solvent A (water
with 0.1% formic acid) and solvent (B) (acetonitrile with
0.1% formic acid) as follows: 10–100% B over 7 min,
followed by isocratic elution with 100% solvent (B) from
7–12.50 min, then returned to 10% from 13 min at a flow
rate of 0.5 ml/min. The column temperature was
maintained at 40°C and the injection volume was 10 μl.
Separation of compounds was monitored with DAD at
254 and 190 nm and with a mass spectrometry detector.
Mass spectrometric analysis (ESI) was carried out
on LCMS-8030 triple-quadrupole mass spectrometer
(Shimadzu, Kyoto, Japan). Liquid chromatography–tandem
mass spectrometry (LC-MS/MS) was set in the negative
and positive ionization mode with spectra acquired over a
mass range of 50–1000 m/z. The acquisition parameters
were as following: interface voltage, 4.5 kV; interface
temperature, 250°C; desolvation line temperature, 250°C;
heat block temperature, 400°C; desolvation gas, nitrogen;
desolvation gas flow rate, 3.0 l/min; drying gas, nitrogen;
drying gas flow rate, 15 l/min; collision gas, argon; and
collision gas pressure, 230 kPa.
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Cell culture
Human melanoma cell line (A375) was derived from the
skin of a 54 year-old female patient with malignant mel-
anoma [18]. This cell line was purchased from the
American Type Culture Collection and cultured in
DMEM media containing 10% Fetal Bovine Serum,
1% penicillin/streptomycin and maintained in a 37°C in-
cubator with 5% CO2. Primary adult human dermal
melanocytes (Cat. No.:2230) were purchased from
Sciencell (Sciencell, San Diego, CA) and maintained in
Melanocyte growth medium (Sciencell). All cells were
maintained in an incubator at 37°C, 5% CO2.
MTT assay
After 24 h of CACF treatment, 50 μl of MTT solution
(2 mg/ml) was transferred to each well. Plates were incu-
bated for 2 h at 37°C. Supernatant was discarded and
DMSO was added to ensure total solubility of formazan
crystals. Absorbance was recorded at 570 nm with Tecan
Infinite®200 Pro microplate reader (Tecan, Männedorf,
Switzerland).
Real time cell growth assay
Cell proliferation was measured using xCELLigence
Real Time Cellular Analysis (RTCA) system (Roche,
Germany), as previously described [19]. Briefly, cells
were seeded at density 1 × 104 on a specialized 16-well
plate with electrodes for 18 h before being treated with
100 μl of CACF at various concentrations and continu-
ously monitored for up to 72 h. Cell index values were
recorded every 5–10 min by RTCA analyzer and nor-
malized to background reading.
Flow cytometry analysis
CACF-treated cells were harvested and stained with FITC-
annexin V and propidium iodide (PI) (BD Biosciences)
in binding buffer for 15 min. Cells were immediately
subjected to flow cytometry analyses using a FACS Canto
II flow cytometer (BD Biosciences). For mitochondria
membrane potential (MMP) measurement, CACF-treated
cells were stained according to the BD™ MitoScreen kit
protocol. Briefly, cells were stained with 0.5 ml of the JC-1
reagent for 15 min, washed and resuspended in 0.5 ml
assay buffer prior to flow cytometric analysis.
Bioluminescent assay for caspase-3/7, -8 and −9 activities
Caspase assay was performed in triplicates using the
Caspase-Glo®-3/7, -8 and −9 assay kits (Promega,
Madison, WI) on a white 96-well microplate. A total
of 1 × 104 cells were seeded per well and treated with
100 μl of CACF for 1, 3, 6, 12, 18, 24 and 30 h. Caspase-
Glo reagent was then added and incubated at room
temperature for 30 min. The caspase activities were
measured using a Infinite®200 Pro microplate reader
(Tecan). In the caspase inhibitor study, cells were treated
for 1 h with inhibitors for pan-caspase (Z-VAD-FMK),
caspase-3 (Z-DEVD-FMK), caspase-9 (Z-LEHD-FMK)
or caspase-8 (Z-IETD-FMK), before CACF treatment.
Transmission electron miscroscopy
Conventional electron microscopy was performed as de-
scribed [20]. Cells were fixed with 2.5% glutaraldehyde
in 0.1 M sodium phosphate buffer at pH 7.4 for 1 h. The
specimens are post-fixed in buffer containing 1% os-
mium tetroxide (OsO4) and 1% potassium ferrocyanide,
dehydrated in a series of graded ethanol solutions, and
embedded in epoxy resin. Ultra-thin sections were col-
lected and stained with uranyl acetate and lead citrate
and observed under transmission electron microscope
(TEM, Leo Libra 120, Germany).
Multiple cytotoxicity assay
Cellomics Multiparameter Cytotoxicity 3 Kit was used as
described previously [21]. Briefly, 24 h post CACF treat-
ment, MMP dye and the cell permeability dye were
added to live cells and incubated for 30 min at 37°C.
Cells were fixed, permeabilized, blocked with 1×
blocking buffer before probing with primary cytochrome
c antibody and secondary DyLightTM 649 conjugated
goat anti-mouse IgG for 1 h each. Plates were analyzed
using the ArrayScan high content screening (HCS) sys-
tem (Cellomics, PA, USA).
ROS assay
A total amount of 1 × 104 cells per well were seeded in
96-well plates overnight prior to incubation with CACF.
At indicated time, 50 μl staining solution (DMEM
containing 500 nM Hoechst 33342 and 2.5 μg/ml
dihydroethidium (DHE) were added and incubated for 30
min at 37°C. Cells were fixed with 3.5% paraformaldeyde
in PBS for 15 min, washed and analyzed using the HCS
system (Cellomics).
Western blot analysis
SDS-PAGE and Western blot analyses were performed as
described with slight modifications [22]. At 24 h post
treatment, cells were lysed in RIPA buffer, loaded onto
10% polyacrylamide gel and transferred to microporous
polyvinylidene difluoride membrane (Milipore). Immuno-
blotting was performed with the anti-Bcl-2 (1:200), anti-
p53 (1:200) (Cell Signaling Technology, Danvers, MA),
and mouse anti-β-actin (1:500) (Sigma) antibodies. Mem-
branes were detected using ECL Plus Chemiluminescence
Reagent (Amersham, Chalfont, UK).
Statistical analysis
Each experiment was performed at least two times. The
data are presented as the mean values ± standard
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deviation (SD). Statistical analysis was performed with
Student’s t-test, *P < 0.05 was considered statistically
significant.
Results
LC-MS/MS analysis
Compounds of CACF were successfully identified using
LC-MS/MS. The UV chromatogram at 190 nm of CACF
is shown in Figure 1. The compounds were identified by
interpreting their mass spectra obtained via their MS, MS/
MS, and UV spectra and comparing their data with those
obtained in the literature. The identified compounds are
as listed (Table 1) including retention times, molecular
weight, protonated and deprotonated molecules ([M+H]+
and [M-H]-), MS/MS fragments, as well as their proposed
identities. Five major peaks were observed in the chro-
matograms of CACF. Three compounds were identified
by comparing their MS and MS/MS fragments data with
those in literature. Peak 2 (Figure 2A), detected at 2.9 min,
showed [M+H]+ at m/z 361 and was tentatively assigned
to the sesquiterpene lactone, vernodaline, previously iso-
lated from Vernonia species [19,23,24]. Its MS/MS
spectrum gave fragmentation ions at m/z 57 and 85 which
were attributable to the side chain of the compound. Peak
3 (Figure 2B), retained at 3.6 min, was identified as
vernudiflorid. It showed molecular ion at m/z 329 [M-1]-
and fragmentation ions at m/z 229 and 99 corresponding
to M- C4H7CO2H. These fragmentations were consistent
with those reported for vernudiflorid, isolated from
Vernonia nudiflora [25]. Peak 5 (Rt, 4.7 min; Figure 2C)
Figure 1 Chemical contents of the chloroform fraction of C. anthelminticum seeds. (A) Photo showing the seeds of C. anthelminticum. (B) LC
chromatogram of CACF monitored at 190 nm. Peak 2, vernodaline; peak 3, vernudiflorid; peak 5, 12,13- dihydroxyoleic acid; peaks 1 and 4, unknown.
Table 1 Summary of compounds identified using MS, MS/MS, and UV spectra
Peak # Rt (min) MW [M+H]+ or [M-H]- +/− Ions MS/MS fragments Tentative identification References
1 2.3 378 377 - 257, 257, 230, 187 unknown
2 3.0 360 361 + 259, 247, 86, 58 vernodaline [18,22,23]
3 3.6 330 329 - 229, 211, 99, 83 vernudiflorid [24]
4 3.8 346 345 - 273, 209, 197,163, 84, 57 unknown
5 4.7 314 313 - 213, 182, 157, 131, 12,13- dihydroxyoleic acid [25,26]
Five peaks in the chromatograms of CACF (Figure 1B) were analyzed. Retention times (Rt), molecular weight (MW), protonated and deprotonated molecules ([M+H]+
and [M-H]-), +/− ions, MS/MS fragments, as well as their proposed identities are as listed. Among the five peaks, 2, 3 and 5 were identified as vernodaline, vernudiflori
and 12,13- dihydroxyol, whereas the identities of minor peaks 1 and 4 remained unknown.
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showed [M-1]- at m/z 313 and fragment ions at m/z 213,
182, 157 and 131. It was tentatively identified as 12,13-
dihydroxyoleic acid. Ions at m/z 182 and 131 were
obtained from the allylic cleavage indicated the double
bond at C9 and C10. Fragment ions at m/z 213 and 157,
derived from the alpha cleavage on the either side of the
OH groups, h confirmed their positions at C12 and C13
[26,27]. This compound has been isolated previously from
the seed of C. anthelminticum and Ochrocarpus africanus.
The minor peaks 1 and 4 eluted at 2.3 and 3.8 min, re-
spectively, were unidentified as their fragment ions did
not match with previously reported compounds.
CACF inhibits cell proliferation of melanoma cells
To evaluate the cytotoxic activity, CACF was tested with
various doses on the human melanoma cell line A375
Figure 2 MS/MS spectra and the corresponding chemical structure of the identified compounds. (A) vernodaline, (B) vernuflorid,
(C) 12,13- dihydroxyoleic acid.
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(highly metastatic, amelanotic) and normal human pri-
mary melanocytes. After 24 and 48 h, cell viability was
analyzed using the end-point MTT assays. CACF
exhibited greatest cytotoxicity on A375 cells with IC50
<10 μg/ml. In contrast, CACF was less toxic to normal
primary melanocytes with IC50 >20 μg/ml, equivalent to
a 2-fold higher selectivity compared to doxorubicin, the
standard drug (Table 2).
Next, we monitored the pattern of real time A375 cell
growth after CACF treatment for 3 consecutive days
using RTCA. In control wells, we observed an exponen-
tial increase of cell growth, as reflected by an increase
normalized cell index (nCI) values. A375 cells treated
with the standard drug, doxorubicin (20 μg/ml) demon-
strated complete cell growth inhibition (Figure 3). A375
cells demonstrated a dose-dependent attenuation of cell
proliferation, when treated with increasing concentra-
tions of CACF (Figure 3). A375 proliferated at a slower
rate at 6.25 μg/ml, whereas proliferation remained static
when treated with 12.5 μg/ml CACF. A sudden decrease
in nCI values was detected about 1–2 h after treatment
with a high concentration (50 μg/ml) of CACF, indicat-
ing acute toxicity at high dosages. Altogether, both MTT
and RTCA results suggest that CACF inhibited cell
proliferation of A375 melanoma cells in dose- and time-
dependent manner.
CACF induces apoptosis in melanoma cells
To determine whether CACF-induced cell growth inhib-
ition was due to apoptotic activity, we stained control or
CACF-treated A375 cells with FITC-conjugated annexin
V and PI. The exposure of phosphatidylinositol of the
plasma membrane indicates early apoptosis and can be
stained by annexin V. As shown in Figure 4A and B, sig-
nificant increase of early (annexin V+, PI-) and late
(annexin V+, PI+) apoptotic cells were detected in A375
following CACF treatment.
We further examined cell morphology by using trans-
mission electron microscopy. Micrographs demonstrated
that untreated control cells presented healthy morphology,
including intact plasma membrane, normal nucleus and
abundant numbers of mitochondria (Figure 4C-I). Upon
CACF treatment, nuclear membrane condensation,
disrupted cell structure and severe plasma membrane
blebling were observed (Figure 4C-II), suggesting
occurence of apoptosis [28]. Other drastic morphological
changes included presence of many vacuoles with un-
known content, probably of lipid origin (Figure 4C-III).
Increased lysosome organelles were also presented in most
of the CACF-treated cells. In the same line, the number of
mitochondria were significantly reduced (Figure 4C-IV).
Note that the mitochondria became swollen with disorga-
nized cristae (Figure 4C-III). These collective data indi-
cated that CACF induced apoptotic cell death in
melanoma A375 cells.
CACF induces high level of ROS
ROS is produced when a cell undergoes chemical or en-
vironmental stress, which can lead to modification of
Table 2 IC50 of CACF or doxorubicin in melanoma A375
cells and normal primary melanocytes determined by
MTT assays after 24 and 48 h treatment
CACF Doxorubicin
IC50 (mean ± SD)
μg/mL
IC50 (mean ± SD)
μg/mL
24 h 48 h 24 h 48 h
A375 9.3 ± 2.5 8.5 ± 1.2 7.6 ± 0.8 6.2 ± 1.5
Primary melanocytes 24.3 ± 4.6 21.5 ± 3.1 8.5 ± 2.5 7.2 ± 2.2
Figure 3 Real time cell growth of CACF-treated melanoma cells. A375 cells were seeded for 18 h before addition of CACF or doxorubicin
(standard drug) at indicated concentrations. Cell growth was monitored by RTCA for up to 90 hours.
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cytoskeletal structure and cell apoptosis. Next, we exam-
ined the ROS level in CACF-treated A375 cells by stain-
ing with DHE dye and viewed under HCS system. ROS
production level was low in DMSO-treated control cells.
However, CACF treatment strongly induced ROS pro-
duction in A375 cells after 8 h (Figure 5).
CACF treatment reduces MMP
Accumulating oxidative damage by ROS can affect the
function and efficiency of mitochondria. To monitor the
integrity of MMP, a membrane-permeable lipophilic cat-
ionic fluorescent probe, JC-1, staining was used (Figure 6A).
In healthy polarized mitochondria, JC-1 molecules accu-
mulate in mitochondria as aggregate, thus rendering strong
red fluorescence emission. However, in apoptotic cells, JC-
1 molecules stay as monomers in the cytoplasm, which can
be reflected by weak red fluorescence emission [24]. Un-
treated A375 cells showed high intensity of JC-1-PE (upper
quadrant). After 12 h CACF treatment, we observed a
dose-dependent reduction of JC-1-PE intensity (lower
Figure 4 Cell apoptosis upon CACF treatment. (A) A375 cells were treated with DMSO or with various concentrations of CACF for 24 h. Cells
were then stained with FITC-Annexin V and PI to analyze early apoptotic (Annexin V+ PI-) and late apoptotic/dead (Annexin V+ PI+) cell fractions
through flow cytometry. (B) Histogram shows the percentages of apoptotic cells for each treated sample at 24 h after CACF treatment. Data were
mean ± SD from 2 independent experiments (*P<0.05). (C) Transmission electron microscopy images of A375 cells untreated or treated with 12.5
μg/ml of CACF for 12 h. (C-I) Representative image of untreated control cells. Intact cell membrane and abundant mitochondria were seen in the
cytoplasm. (C-II-IV) Representative images of CACF (12.5 μg/mL)-treated cells. (C-II) Plasma membrane (PM) blebing and nuclear chromatin (CHR)
condensation. (C-III) Increased numbers of clear vacuoles (V) with some lipid-filled vacuoles (LV). Reduced mitochondria copy number and
disrupted cristae in the abnormally swollen mitochondria. (C-IV) Increased numbers of lysosome (LY) organelles.
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quadrant) in melanoma cell indicating impaired MMP
(Figure 6B).
CACF treatment increases nuclear condensation, plasma
membrane permeability and cytochrome c release
Next, we utilised the multiparameter cytotoxicity kit 3
from Cellomics to examine the effect of CACF on other
subcellular structures. For this purpose, we stained A375
cells with Hoechst 33342, a membrane permeability dye,
MMP and cytochrome c antibody. The stained samples
were visualized with the HSC system. In control cells,
cytochrome c distributed evenly and colocalized with
MMP. However, in CACF-treated cells, cytochrome c
stained strongly in the cytosol, indicating CACF-induced
cytochrome c release from the mitochondria (Figure 7A).
In addition, we observed a dose-dependent increase of
nuclear condensation, increased membrane permeability
and decreased MMP stain in CACF-treated melanoma
cells (Figure 7A-E).
CACF induces caspase-9, -3/7 activity
Apoptosis is a complex phenomenon that mobilizes a
number of molecules and is classified into caspase-
dependent or caspase-independent mechanisms. To
examine the molecular mechanism underlying the apop-
tosis process in CACF-treated A375 cells, we incubated
cells with aminoluciferin-labeled caspase substrate, and
caspase activities were determined by measuring lumi-
nescence intensities. After CACF administration, the ac-
tivities of caspase-3/7, -8 and −9 were monitored for a
period of 30 h. We observed a gradual increase of
caspase-9 and 3/7 activities after 3 h treatment in A375
cells (Figure 8A). In contrast, there were no significant
changes in caspase-8 activity throughout 30 h.
To further confirm this, we treated melanoma cells
with specific caspase inhibitors. Pre-treatment with the
pan-caspase (Z-VAD-FMK), caspase-3 (Z-DEVD-FMK)
or caspase-9 (Z-LEHD-FMK) inhibitors, significantly im-
paired caspase-3/7 activity (Figure 8B). However, intro-
duction of the caspase-8 inhibitor (Z-IETD-FMK) showed
no significant inhibitory effect, suggesting that CACF-
induced apoptosis occurred through the intrinsic, but not
the extrinsic caspase pathway.
CACF downregulates Bcl-2, upregulates p53 expression
levels and inhibits TNF-α–induced NF-κB nuclear
translocation
The anti-apoptotic molecule Bcl-2 is a key regulator of
cell death and cell proliferation. Loss of Bcl-2 may lead
to apoptosis activity, while enforced Bcl-2 expression in
apoptotic cells inhibits cell death. To investigate the
mechanism underlying CACF-induced cell death, we
performed Western blotting to examine the expression
level of Bcl-2 in human melanoma cells with/without
CACF treatment for 24 h. Interestingly, we found that
CACF dose-dependently downregulated Bcl-2 expression
in A375 cells (Figure 9A).
One of the molecules that negatively regulates Bcl-2 is
the p53 tumor suppressor protein. The p53 molecule is
also frequently upregulated in response to DNA damage
to exert cell cylce arrest [29]. Owing to this, we pre-
dicted that p53 expression could be affected upon CACF
treatment. As shown in Figure 9A, we demonstrated that
CACF markedly increased the expression of p53 protein
in melanoma cells.
The NF-κB pathway confers resistance to apoptosis
through induction of Bcl-2 expression [30]. We hypothe-
sized that reduced Bcl-2 expression may be due to inhib-
ition of the NF-κB pathway. To address this, we treated
A375 cells with CACF prior to addition of TNF-α. Cells
were fixed, stained and visualized as described in the
Materials and Methods. In the absence of TNF-α
(−TNF), NF-κB remained in the cytoplasm (Figure 9B).
TNF-α stimulation (+TNF) led to translocation of NF-
Figure 5 ROS generation in CACF-treated cells. (A) A375 cells
were treated with DMSO or with 12.5 μg/ml concentration of CACF
for 8 h, stained with DHE dye and visualized under HSC array scan
reader. (B) Average fluorescence intensities of DHE dye in A375 cells
treated with CACF or doxorubicin. Data were mean ± SD of
fluorescence intensity readings measured from different photos
taken (*P<0.05).
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κB from cytoplasm to the nucleus (Figure 9B). Interest-
ingly, NF-κB nuclear translocation induced by TNF-α
was significantly inhibited at 12.5 μg/ml and 25 μg/ml of
CACF (Figure 9B and C). Mechanism of NF-κB nuclear
translocation involves cascade reactions including the
phosphorylation activity by IκB kinase (IKK), ubiquitin-
dependent degradation of IκB and dissociation of NF-κB
from the IκB complex. Therefore, CACF may interrupt
these activities downstream of TNF signaling pathway
which prevent NF-κB nuclear migration. Together, these
data suggest a potential interplay between NF-κB and
apoptosis pathway molecules during CACF treatment
(Figure 10).
Discussion
Malignant melanoma remains a great challenge due to its
significant resistance to chemotherapeutic treatments,
which is mostly caused by an intrinsic resistance of the neo-
plastic melanocytes to undergo apoptosis [31]. Although
both active and passive immunotherapy have been pursued
vigorously over the past few decades, no melanoma vaccine
has proven effective, and only interleukin 2 therapy has led
to durable remission in only 5–8% of patients treated [32].
In this context, plant-derived compounds play an important
role in the development of new anti-cancer agents against
human melanoma.
In this study, the fraction of CACF was analyzed by
LCMS-IT-TOF, in order to correlate the activity of
CACF with its components. Vernodalin, a sesquiterpene
lactone, was the predominant compound in the CACF
fraction. In 1969, an investigation by Kupchan et al. [23]
revealed tumor inhibitory activity of vernodalin against
cells derived from human carcinoma of the nasopharynx
(KB). Similar findings were reported by Kasim et al. in
2011, where vernodalin indicated significant cytotoxic
activity against the melanoma (Sk-mel 28) and ovarian
cancer (CAOV-3) cell lines [33]. Recently, our group
showed that vernodalin possessed strong cytotoxicity
against the breast cancer cell line (MCF7) via the
caspase pathway [19]. Thus, vernodalin could be the
cytotoxic compound responsible for the CACF-induced
cell growth inhibition in melanoma cells, although fur-
ther research is needed to verify this.
Our collective data suggest that A375 melanoma cells
undergo apoptotic cell death after treatment with CACF.
During early apoptosis, the mitochondrial transmem-
brane depolarizes, followed by cytochrome c leakage
which triggers caspase cascade activation [28]. Caspases
belong to family of cysteine proteases that are divided
into executioner (caspase-3 or −7) and initiator
(caspase-8 or −9) caspases. Initiator caspase-8 is known
to be activated through the extrinsic pathway, whereas
Figure 6 JC-1 intensity in CACF-treated cells. (A) A375 cells were treated with indicated concentrations of CACF for 12 h. Cells were then
collected, stained and analyzed with the flow cytometer. (B) Bar chart shows the mean fluorescence intensity of JC-1-PE. Dose-dependent-
reduction of JC-1-PE by CACF treatment was observed. Data were mean ± SD of fluorescence intensity readings from two independent
experiments (*P<0.05).
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caspase-9 is activated in the intrinsic event of mitochon-
drial cytochrome c leakage. Both of these initiator
caspases lead to downstream activation of executioner
caspase-3 or −7, which triggers cell apoptosis [34]. Incu-
bation with CACF resulted in a time-dependent activa-
tion of caspase-9, whereas caspase-8 was rather
unaffected throughout the period of study. In addition,
treatments with Z-VAD-FMK, Z-DEVD-FMK or Z-
LEHD-FMK caspase inhibitors significantly impaired
caspase-3/7 activities. Thus, our results clearly implicate
the involvement of the mitochondria-dependent intrinsic
apoptotic pathway in CACF-induced melanoma cell
death.
ROS are highly reactive molecules that can oxidize
lipids, proteins, and DNA. Mitochondria provide meta-
bolic energy through oxidative phosphorylation and gen-
erate ROS as normal side product. Natural compounds
(e.g. curcumin) or anti-cancer drug (e.g. doxorubicin)
Figure 7 Effect of CACF on MMP, permeability and cytochrome c release. (A) Representative images of A375 cells treated with medium
alone and 12.5 μg/ml of CACF, and stained with Hoechst for nuclear, cell permeability dye, MMP and cytochrome c. The images from each row
were obtained from the same field of each sample (20×). (B-E) Average fluorescence intensities of Hoechst 33342, cell permeability dye, MMP
and cytochrome c in A375 cells treated with CACF or standard drug doxorubicin. Data were mean ± SD of fluorescence intensity readings
measured from different photos taken (*P<0.05).
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can upregulate intracellular ROS level and signal cells to
differentiate or undergo apoptosis. Excessive production
of ROS by CACF could destroy MMP (marked by low
JC-1 staining), which eventually leads to release of
proapoptotic transducing molecules such as cytochrome
c. In addition, ROS could also destroy plasma membrane
and DNA, resulting in higher membrane permeability
staining and DNA fragmentation, as observed in this
study [35].
In this study, we found that anti-cancer activity of
CACF may be attributed to Bcl-2 downregulation in
melanoma cells. It is well established that Bcl-2 generally
Figure 8 Caspase activities in CACF-treated cells. (A) Caspase-
3/7, -8 and −9 activities in the CACF (12.5 μg/mL)-treated A375 cells
were measured in luminescence against various time intervals.
Activity of caspase-9 was increased followed by caspase-3/7
activities after CACF treatment. (B) A375 cells were pretreated with
inhibitors for pan-caspase (Z-VAD-FMK), caspase-3 (Z-DEVD-FMK),
caspase-9 (Z-LEHD-FMK) or caspase-8 (Z-IETD-FMK) before adding
CACF. Caspase-3/7 activities in CACF-treated cells were then
determined by luminescence assays. Data were mean ± SD of
fluorescence intensity readings measured from different photos
taken (*P<0.05).
Figure 9 Bcl-2, p53 expression and TNF-α-induced NF-κB
translocation in CACF-treated cells. (A) A375 cells were treated
with various concentrations of CACF for 24 h. Cells were harvested
and lysed for Western blot analysis. Membranes were probed with
anti-Bcl-2, anti-p53 or anti-β-actin antibodies. Data were
representative of two independent experiments. (B) A375 cells were
pretreated with various concentrations of CACF prior to stimulation
with 10 ng/ml TNF-α for 30 min. Cells were fixed, stained for NF-κB
and visualized using HSC. (C) Bar chart showing the average
fluorescence intensities of nuclear NF-κB in control/treated A375
cells in the absence/presence of TNF-α.
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acts as a potent anti-apoptosis gene by controlling sev-
eral key steps in apoptosis signaling, including formation
of ion channels in biological membranes that influence
permeability of intracellular membranes and cytochrome
c release from mitochondria. Therapeutic agents that
target Ras/Raf signaling often face a resistance problem,
whereas a new strategy that target the survival Bcl-2
family proteins (Mcl-1 and A1) has been successful and
further enhanced with chemotherapy [36]. Thus, Bcl-2
downregulation by CACF is an effective way in sensitiz-
ing human melanoma cells to apoptosis.
In addition to the anti-apoptotic Bcl-2 molecule, we
showed that p53 expression is up-regulated in CACF-
treated melanoma cells. Increased p53 may be triggered
by nuclear fragmentation to repair DNA damage. Loss
of p53 expression in mice and in human melanocytes
has been shown to increase the proliferation and in vivo
tumourigenicity, concordant with the role of p53 as a
tumour suppressor [37,38]. Interestingly, we also showed
that NF-κB translocation into the nucleus is inhibited by
CACF, which could subsequently affect the expression
levels of Bcl-2 and p53, because both of these molecules
are downsream transcription targets of the NF-κB path-
way [30,39,40].
In this study, we have demonstrated anti-cancer activ-
ity of CACF on human malignant melanoma A375 cell
line. The limitation of the current study can be further
expanded in future investigations by evaluating CACF
therapeutic effects on other melanoma cell lines or
in vivo xenograft model. These findings will help to ex-
plore the applicability of the plant extract and its constit-
uents on skin cancers.
Conclusion
This report shows that CACF has profound cytotoxic ac-
tivity against human melanoma cells, but not normal
melanocytes, by inducing apoptosis through modulation
of anti- and pro-apoptotic signaling pathways (Figure 10).
CACF induces intracellular ROS generation, which
causes DNA damage, increased membrane permeability
and activation of a mitochondria-dependent caspase cas-
cade. These effects induce upregulation of p53 and
downregulation of Bcl-2, which commit cells to apop-
tosis. In addition, CACF also inhibits pro-survival signal-
ing by preventing NF-κB nuclear translocation. Together,
our findings further support the development of CACF
as an alternative therapeutic agent against melanoma
malignancy.
Figure 10 Schematic model of cell death mechanism in CACF-induced responses in melanoma A375 cells. CACF induces intracellular ROS
production due to elevated oxidative stress. This initiates various intracellular changes including increased membrane permeability and reduced
MMP which subsequently causes cytochrome c release from the mitochondria. Cytoplasmic cytochrome c activates caspase pathway molecules,
including caspase-9 and caspase-3/7. Activation of caspase molecules subsequently leads to nuclear fragmentation. CACF treatment also triggers
p53 expression that may initiate apoptosis activity through reduction of anti-apoptotic Bcl-2 level. On the other hand, CACF prevented NF-κB
nuclear translocation, which could induce Bcl-2 transactivation and maintain cell survival in A375 melanoma cells.
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